Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use.
暂无分享,去创建一个
P. Robledo | L. Pardo | C. Correll | R. de la Torre | V. Casadó | A. Cuenca-Royo | L. Galindo | E. Moreno | E. Canela | A. Cordomí | D. Guinart | E. Pérez | V. Pérez | M. Barrera-Conde | Cristina Fernández-Avilés
[1] L. Pardo,et al. Control of glutamate release by complexes of adenosine and cannabinoid receptors , 2020, BMC Biology.
[2] Sarah L. Withey,et al. Δ-Tetrahydrocannabinol Increases Dopamine D1-D2 Receptor Heteromer and Elicits Phenotypic Reprogramming in Adult Primate Striatal Neurons , 2019, iScience.
[3] Andrea Cipriani,et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis , 2019, The Lancet.
[4] Eduard Bentea,et al. Kinase network dysregulation in a human induced pluripotent stem cell model of DISC1 schizophrenia. , 2019, Molecular omics.
[5] E. Vieta,et al. Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis , 2019, European Neuropsychopharmacology.
[6] R. Murray,et al. High-potency cannabis and incident psychosis: correcting the causal assumption - Authors' reply. , 2019, Lancet psychiatry.
[7] S. Iwata,et al. Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine , 2019, Nature Structural & Molecular Biology.
[8] S. Iwata,et al. Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine , 2019, Nature Structural & Molecular Biology.
[9] I. Ibarra-Lecue,et al. Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway , 2018, Neuropsychopharmacology.
[10] G. Benítez-King,et al. Exfoliated Human Olfactory Neuroepithelium: A Source of Neural Progenitor Cells , 2018, Molecular Neurobiology.
[11] P. Robledo,et al. Cannabis Users Show Enhanced Expression of CB1-5HT2A Receptor Heteromers in Olfactory Neuroepithelium Cells , 2018, Molecular Neurobiology.
[12] J. Kane,et al. Improving outcomes of first‐episode psychosis: an overview , 2017, World psychiatry : official journal of the World Psychiatric Association.
[13] C. Trueta,et al. The role of melatonin in the neurodevelopmental etiology of schizophrenia: A study in human olfactory neuronal precursors , 2017, Journal of pineal research.
[14] Jarek Meller,et al. Abnormalities of signal transduction networks in chronic schizophrenia , 2017, npj Schizophrenia.
[15] Yongchao Ge,et al. Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects , 2017, Nature Neuroscience.
[16] Shan Jiang,et al. Crystal structures of agonist-bound human cannabinoid receptor CB1 , 2017, Nature.
[17] M. García-Anaya,et al. Human neural stem/progenitor cells derived from the olfactory epithelium express the TrkB receptor and migrate in response to BDNF , 2017, Neuroscience.
[18] A. Sawa,et al. Application of olfactory tissue and its neural progenitors to schizophrenia and psychiatric research , 2017, Current opinion in psychiatry.
[19] M. Parellada,et al. Cannabis use, COMT, BDNF and age at first-episode psychosis , 2017, Psychiatry Research.
[20] M. Clarke,et al. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode , 2017, BMJ Open.
[21] Peter B. Jones,et al. Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort , 2017, Psychiatry Research.
[22] Robin M. Murray,et al. The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia , 2017, Biological Psychiatry.
[23] C. Trueta,et al. The microtubular cytoskeleton of olfactory neurons derived from patients with schizophrenia or with bipolar disorder: Implications for biomarker characterization, neuronal physiology and pharmacological screening , 2016, Molecular and Cellular Neuroscience.
[24] S. Łukasiewicz,et al. Dopamine D2 and serotonin 5‐HT1A receptor interaction in the context of the effects of antipsychotics – in vitro studies , 2016, Journal of neurochemistry.
[25] J. C. Morales-Medina,et al. Neuronal and brain morphological changes in animal models of schizophrenia , 2016, Behavioural Brain Research.
[26] C. Chiou,et al. Global economic burden of schizophrenia: a systematic review , 2016, Neuropsychiatric disease and treatment.
[27] M. Packard,et al. The influence of cannabinoids on learning and memory processes of the dorsal striatum , 2015, Neurobiology of Learning and Memory.
[28] V. Pérez,et al. Predictors of Relapse and Functioning in First-Episode Psychosis: A Two-Year Follow-Up Study. , 2015, Psychiatric services.
[29] P. Robledo,et al. Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors , 2015, PLoS biology.
[30] Karin E. Borgmann-Winter,et al. Translational potential of olfactory mucosa for the study of neuropsychiatric illness , 2015, Translational Psychiatry.
[31] E. Velthorst,et al. Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study , 2015, Psychological Medicine.
[32] R. Keefe. The longitudinal course of cognitive impairment in schizophrenia: an examination of data from premorbid through posttreatment phases of illness. , 2014, The Journal of clinical psychiatry.
[33] A. Bachoud-Lévi,et al. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis , 2014, European Journal of Clinical Pharmacology.
[34] E P Noble,et al. Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients , 2014, Translational Psychiatry.
[35] H. Okano,et al. Olfactory cells via nasal biopsy reflect the developing brain in gene expression profiles: Utility and limitation of the surrogate tissues in research for brain disorders , 2013, Neuroscience Research.
[36] J. González-Maeso,et al. Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects , 2013, European Neuropsychopharmacology.
[37] A. Mackay-Sim. Concise Review: Patient‐Derived Olfactory Stem Cells: New Models for Brain Diseases , 2012, Stem cells.
[38] Robert B. Innis,et al. Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia , 2012, Schizophrenia Research.
[39] M. Ferrín,et al. Neurological soft signs in patients with psychosis and cannabis abuse: a systematic review and meta-analysis of paradox. , 2012, Current pharmaceutical design.
[40] John M. Davis,et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis , 2012, The Lancet.
[41] D. Kelly,et al. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements , 2012 .
[42] L. Pardo,et al. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.
[43] Deanna M. Barch,et al. Cognition in schizophrenia: core psychological and neural mechanisms , 2012, Trends in Cognitive Sciences.
[44] G. Benítez-King,et al. A non-invasive method to isolate the neuronal linage from the nasal epithelium from schizophrenic and bipolar diseases , 2011, Journal of Neuroscience Methods.
[45] Jessica A. Turner,et al. Identifying gene regulatory networks in schizophrenia , 2010, NeuroImage.
[46] C. Wells,et al. Disease-specific, neurosphere-derived cells as models for brain disorders , 2010, Disease Models & Mechanisms.
[47] W. Koltun,et al. Primary cell lines: false representation or model system? a comparison of four human colorectal tumors and their coordinately established cell lines. , 2010, International journal of clinical and experimental medicine.
[48] J. Kleinman,et al. Epigenetic mechanisms in schizophrenia. , 2009, Biochimica et biophysica acta.
[49] S. Faraone,et al. Neurocognition in first-episode schizophrenia: a meta-analytic review. , 2009, Neuropsychology.
[50] J. Fernández-Ruiz. The endocannabinoid system as a target for the treatment of motor dysfunction , 2009, British journal of pharmacology.
[51] G. Kinsella,et al. Effect of age on forward and backward span tasks , 2004, Journal of the International Neuropsychological Society.
[52] J. Sweatt,et al. Mitogen-activated protein kinases in synaptic plasticity and memory , 2004, Current Opinion in Neurobiology.
[53] Therese Garrick,et al. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[54] Jeffrey A Lieberman,et al. Recent advances in the neurobiology of schizophrenia. , 2003, Molecular interventions.
[55] Robin M. Murray,et al. Neurological soft signs in first-episode psychosis: A systematic review , 2002, British Journal of Psychiatry.
[56] N. Darmani. Cannabinoids of diverse structure inhibit two DOI-induced 5-HT2A receptor-mediated behaviors in mice , 2001, Pharmacology Biochemistry and Behavior.
[57] A. Baddeley,et al. The Quarterly Journal of Experimental Psychology Section a Human Experimental Psychology Dementia and Working Memory Dementia and Working Memory , 2022 .
[58] D. Moran,et al. The fine structure of the olfactory mucosa in man , 1982, Journal of neurocytology.
[59] Dan J Stein,et al. Polygenic risk for schizophrenia and associated brain structural changes: A systematic review. , 2019, Comprehensive psychiatry.
[60] Julie Kreyenbuhl,et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. , 2010, Schizophrenia bulletin.
[61] J. Lieberman,et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs , 2005, Molecular Psychiatry.